Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies

ABSTRACT Astegolimab, a fully human immunoglobulin G2 monoclonal antibody, binds with high affinity to ST2, the interleukin‐33 receptor, thereby blocking ST2/interleukin‐33 binding and subsequent inflammatory cascades involved in inflammatory diseases. Here, we present three randomized, double‐blind...

Descrición completa

Detalles Bibliográficos

Principais autores:	Wenhui Zhang, Dorothy Cheung, Alice Fong, Logan Brooks, Michele A. Grimbaldeston, Audrey Arjomandi, Xiaoying Yang, Ajit Dash, Hansen Wong, Jane R. Parnes, Divya Mohan
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-10-01
Series:	Clinical and Translational Science
Assuntos:	monoclonal antibodies pharmacokinetics phase 1 safety
Acceso en liña:	https://doi.org/10.1111/cts.70338
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!